Evaluation and comparison of two new prostate carcinoma markers: Free‐prostate specific antigen and prostate specific membrane antigen
BACKGROUND Two new prostate cancer markers, free‐prostate specific antigen (f‐PSA) and prostate specific membrane antigen (PSMA) were recently introduced. This report summarizes a prospective two‐year multicenter test of their diagnostic or prognostic capabilities. Total PSA was also measured. METHO...
Gespeichert in:
| Veröffentlicht in: | Cancer 1996-08, Vol.78 (4), p.809-818 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 818 |
|---|---|
| container_issue | 4 |
| container_start_page | 809 |
| container_title | Cancer |
| container_volume | 78 |
| creator | Murphy, Gerald P. Barren, Robert J. Erickson, Sheila J. Bowes, Victoria A. Wolfert, Robert L. Bartsch, Georg Klocker, Helmut Pointner, Joseph Reissigl, A. McLeod, David G. Douglas, Thomas Morgan, Ted Kenny, Gerald M. Ragde, Haakon Boynton, Alton L. Holmes, Eric H. |
| description | BACKGROUND
Two new prostate cancer markers, free‐prostate specific antigen (f‐PSA) and prostate specific membrane antigen (PSMA) were recently introduced. This report summarizes a prospective two‐year multicenter test of their diagnostic or prognostic capabilities. Total PSA was also measured.
METHODS
There were four clinical groups studied: (1) 226 individuals from a screening project undergoing ultrasound and biopsy evaluation had markers obtained: (2) 68 patients suspected of having prostate cancer and undergoing 2 or more biopsies had the markers obtained on multiple occasions: (3) 100 patients undergoing radical prostatectomy had markers obtained pre‐ and post‐operatively: and (4) 31 patients with metastatic prostate cancer each had multiple samples for marker assay obtained over a 2‐year period. In all, 465 patients had one or more samples obtained and studied.
RESULTS
Free‐PSA affords little additional diagnostic advantage compared with total PSA in the screening population. The reciever operating characteristic curves for diagnostic accuracy were ranked: (1) PSA density; (2) total PSA; (3) f‐PSA; and (4) PSMA. PSMA showed the best correlation with stage of the primary tumor in the screened group. In the multiple negative biopsy group, f‐PSA varied from 12 to 21%. PSMA values were evaluated in all histologic categories. PSA density was; ce0.15 in all categories. In the prostatectomy cases PSA values postoperatively were quite low in Stage II; f‐PSA was of no value. Later, f‐PSA was increased in association with elevated total PSA values. Mean PSMA values were above normal in all postoperative time periods except in Stage III patients at 6 months to 1 year postoperatively. PSA densities were all; ce0.15. In patients with metastatic carcinoma, elevated PSMA values correlated best with a poor prognosis (clinical progression), as has been described.
CONCLUSIONS
These data suggest that f‐PSA values do not provide additional diagnostic benefit compared with total PSA in screening populations, in the presence of suspected cancer, postprostatectomy, or in metastatic disease. PSMA is of prognostic significance, especially in the presence of metastatic disease, and correlates well with the stage of disease in cancers detected in a screened population. Cancer 1996;78:809‐18. |
| doi_str_mv | 10.1002/(SICI)1097-0142(19960815)78:4<809::AID-CNCR18>3.0.CO;2-Z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78231718</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78231718</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4798-c0833ca6ed25e0893ff3827c9525676716ed61553e7cded4f7c0acd9ef0b53753</originalsourceid><addsrcrecordid>eNqFkUtvEzEUhS0EKqHwE5BmgVC7mODHeGynCFENLUSqiMRDqrK5cjx3kGEeYTwh6o4lS34jvwRHmWZTJFbW9Tk--nwPIa8ZnTJK-YuTj_NifsqoUSllGT9hxuRUM3mq9Cx7qamZzc7nb9LiffGB6VdiSqfF4oyny3tkcnh0n0wopTqVmbh-SB6F8DWOiktxRI60krlQ-YT8uvhh640dfNcmti0T1zVr2_sQx65Khm2XtLhN1n0XBjtg4mzvfNs1Nmls_w37MEsue8Q_P38fLGGNzlfexbjBf8F97F21wWbV2xZvbY_Jg8rWAZ-M5zH5fHnxqXiXXi3ezovzq9RlyujUUS2EszmWXCLVRlSV0Fw5I7nMVa5YVHImpUDlSiyzSjlqXWmwoisplBTH5Pk-NyJ932AYoPHBYV1Hlm4TQGkumGI6Gq_3RhfZQ48VrHsff30DjMKuJIBdSbDbN-z2DbclxQzIIJYEEEuCfUkggEKxAA7LGP10ZNisGiwPwWMrUX826jY4W1dxT86Hg02w3PDMRNtyb9v6Gm_u4P2X7p9w4434C7NMvv8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78231718</pqid></control><display><type>article</type><title>Evaluation and comparison of two new prostate carcinoma markers: Free‐prostate specific antigen and prostate specific membrane antigen</title><source>MEDLINE</source><source>Wiley Online Library Free Content</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Murphy, Gerald P. ; Barren, Robert J. ; Erickson, Sheila J. ; Bowes, Victoria A. ; Wolfert, Robert L. ; Bartsch, Georg ; Klocker, Helmut ; Pointner, Joseph ; Reissigl, A. ; McLeod, David G. ; Douglas, Thomas ; Morgan, Ted ; Kenny, Gerald M. ; Ragde, Haakon ; Boynton, Alton L. ; Holmes, Eric H.</creator><creatorcontrib>Murphy, Gerald P. ; Barren, Robert J. ; Erickson, Sheila J. ; Bowes, Victoria A. ; Wolfert, Robert L. ; Bartsch, Georg ; Klocker, Helmut ; Pointner, Joseph ; Reissigl, A. ; McLeod, David G. ; Douglas, Thomas ; Morgan, Ted ; Kenny, Gerald M. ; Ragde, Haakon ; Boynton, Alton L. ; Holmes, Eric H.</creatorcontrib><description>BACKGROUND
Two new prostate cancer markers, free‐prostate specific antigen (f‐PSA) and prostate specific membrane antigen (PSMA) were recently introduced. This report summarizes a prospective two‐year multicenter test of their diagnostic or prognostic capabilities. Total PSA was also measured.
METHODS
There were four clinical groups studied: (1) 226 individuals from a screening project undergoing ultrasound and biopsy evaluation had markers obtained: (2) 68 patients suspected of having prostate cancer and undergoing 2 or more biopsies had the markers obtained on multiple occasions: (3) 100 patients undergoing radical prostatectomy had markers obtained pre‐ and post‐operatively: and (4) 31 patients with metastatic prostate cancer each had multiple samples for marker assay obtained over a 2‐year period. In all, 465 patients had one or more samples obtained and studied.
RESULTS
Free‐PSA affords little additional diagnostic advantage compared with total PSA in the screening population. The reciever operating characteristic curves for diagnostic accuracy were ranked: (1) PSA density; (2) total PSA; (3) f‐PSA; and (4) PSMA. PSMA showed the best correlation with stage of the primary tumor in the screened group. In the multiple negative biopsy group, f‐PSA varied from 12 to 21%. PSMA values were evaluated in all histologic categories. PSA density was; ce0.15 in all categories. In the prostatectomy cases PSA values postoperatively were quite low in Stage II; f‐PSA was of no value. Later, f‐PSA was increased in association with elevated total PSA values. Mean PSMA values were above normal in all postoperative time periods except in Stage III patients at 6 months to 1 year postoperatively. PSA densities were all; ce0.15. In patients with metastatic carcinoma, elevated PSMA values correlated best with a poor prognosis (clinical progression), as has been described.
CONCLUSIONS
These data suggest that f‐PSA values do not provide additional diagnostic benefit compared with total PSA in screening populations, in the presence of suspected cancer, postprostatectomy, or in metastatic disease. PSMA is of prognostic significance, especially in the presence of metastatic disease, and correlates well with the stage of disease in cancers detected in a screened population. Cancer 1996;78:809‐18.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19960815)78:4<809::AID-CNCR18>3.0.CO;2-Z</identifier><identifier>PMID: 8756376</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antigens, Neoplasm - analysis ; Antigens, Neoplasm - blood ; Antigens, Surface - analysis ; Antigens, Surface - blood ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - blood ; Biopsy ; Evaluation Studies as Topic ; free‐prostate specific antigen ; Glutamate Carboxypeptidase II ; Humans ; Male ; Medical sciences ; Neoplasm Staging ; Nephrology. Urinary tract diseases ; Prognosis ; Prospective Studies ; prostate specific antigen ; prostate specific membrane antigen ; Prostate-Specific Antigen - analysis ; Prostate-Specific Antigen - blood ; Prostatectomy ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - chemistry ; Prostatic Neoplasms - diagnosis ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Cancer, 1996-08, Vol.78 (4), p.809-818</ispartof><rights>Copyright © 1996 American Cancer Society</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4798-c0833ca6ed25e0893ff3827c9525676716ed61553e7cded4f7c0acd9ef0b53753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291097-0142%2819960815%2978%3A4%3C809%3A%3AAID-CNCR18%3E3.0.CO%3B2-Z$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291097-0142%2819960815%2978%3A4%3C809%3A%3AAID-CNCR18%3E3.0.CO%3B2-Z$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3169249$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8756376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murphy, Gerald P.</creatorcontrib><creatorcontrib>Barren, Robert J.</creatorcontrib><creatorcontrib>Erickson, Sheila J.</creatorcontrib><creatorcontrib>Bowes, Victoria A.</creatorcontrib><creatorcontrib>Wolfert, Robert L.</creatorcontrib><creatorcontrib>Bartsch, Georg</creatorcontrib><creatorcontrib>Klocker, Helmut</creatorcontrib><creatorcontrib>Pointner, Joseph</creatorcontrib><creatorcontrib>Reissigl, A.</creatorcontrib><creatorcontrib>McLeod, David G.</creatorcontrib><creatorcontrib>Douglas, Thomas</creatorcontrib><creatorcontrib>Morgan, Ted</creatorcontrib><creatorcontrib>Kenny, Gerald M.</creatorcontrib><creatorcontrib>Ragde, Haakon</creatorcontrib><creatorcontrib>Boynton, Alton L.</creatorcontrib><creatorcontrib>Holmes, Eric H.</creatorcontrib><title>Evaluation and comparison of two new prostate carcinoma markers: Free‐prostate specific antigen and prostate specific membrane antigen</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
Two new prostate cancer markers, free‐prostate specific antigen (f‐PSA) and prostate specific membrane antigen (PSMA) were recently introduced. This report summarizes a prospective two‐year multicenter test of their diagnostic or prognostic capabilities. Total PSA was also measured.
METHODS
There were four clinical groups studied: (1) 226 individuals from a screening project undergoing ultrasound and biopsy evaluation had markers obtained: (2) 68 patients suspected of having prostate cancer and undergoing 2 or more biopsies had the markers obtained on multiple occasions: (3) 100 patients undergoing radical prostatectomy had markers obtained pre‐ and post‐operatively: and (4) 31 patients with metastatic prostate cancer each had multiple samples for marker assay obtained over a 2‐year period. In all, 465 patients had one or more samples obtained and studied.
RESULTS
Free‐PSA affords little additional diagnostic advantage compared with total PSA in the screening population. The reciever operating characteristic curves for diagnostic accuracy were ranked: (1) PSA density; (2) total PSA; (3) f‐PSA; and (4) PSMA. PSMA showed the best correlation with stage of the primary tumor in the screened group. In the multiple negative biopsy group, f‐PSA varied from 12 to 21%. PSMA values were evaluated in all histologic categories. PSA density was; ce0.15 in all categories. In the prostatectomy cases PSA values postoperatively were quite low in Stage II; f‐PSA was of no value. Later, f‐PSA was increased in association with elevated total PSA values. Mean PSMA values were above normal in all postoperative time periods except in Stage III patients at 6 months to 1 year postoperatively. PSA densities were all; ce0.15. In patients with metastatic carcinoma, elevated PSMA values correlated best with a poor prognosis (clinical progression), as has been described.
CONCLUSIONS
These data suggest that f‐PSA values do not provide additional diagnostic benefit compared with total PSA in screening populations, in the presence of suspected cancer, postprostatectomy, or in metastatic disease. PSMA is of prognostic significance, especially in the presence of metastatic disease, and correlates well with the stage of disease in cancers detected in a screened population. Cancer 1996;78:809‐18.</description><subject>Antigens, Neoplasm - analysis</subject><subject>Antigens, Neoplasm - blood</subject><subject>Antigens, Surface - analysis</subject><subject>Antigens, Surface - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biopsy</subject><subject>Evaluation Studies as Topic</subject><subject>free‐prostate specific antigen</subject><subject>Glutamate Carboxypeptidase II</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasm Staging</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>prostate specific antigen</subject><subject>prostate specific membrane antigen</subject><subject>Prostate-Specific Antigen - analysis</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - chemistry</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtvEzEUhS0EKqHwE5BmgVC7mODHeGynCFENLUSqiMRDqrK5cjx3kGEeYTwh6o4lS34jvwRHmWZTJFbW9Tk--nwPIa8ZnTJK-YuTj_NifsqoUSllGT9hxuRUM3mq9Cx7qamZzc7nb9LiffGB6VdiSqfF4oyny3tkcnh0n0wopTqVmbh-SB6F8DWOiktxRI60krlQ-YT8uvhh640dfNcmti0T1zVr2_sQx65Khm2XtLhN1n0XBjtg4mzvfNs1Nmls_w37MEsue8Q_P38fLGGNzlfexbjBf8F97F21wWbV2xZvbY_Jg8rWAZ-M5zH5fHnxqXiXXi3ezovzq9RlyujUUS2EszmWXCLVRlSV0Fw5I7nMVa5YVHImpUDlSiyzSjlqXWmwoisplBTH5Pk-NyJ932AYoPHBYV1Hlm4TQGkumGI6Gq_3RhfZQ48VrHsff30DjMKuJIBdSbDbN-z2DbclxQzIIJYEEEuCfUkggEKxAA7LGP10ZNisGiwPwWMrUX826jY4W1dxT86Hg02w3PDMRNtyb9v6Gm_u4P2X7p9w4434C7NMvv8</recordid><startdate>19960815</startdate><enddate>19960815</enddate><creator>Murphy, Gerald P.</creator><creator>Barren, Robert J.</creator><creator>Erickson, Sheila J.</creator><creator>Bowes, Victoria A.</creator><creator>Wolfert, Robert L.</creator><creator>Bartsch, Georg</creator><creator>Klocker, Helmut</creator><creator>Pointner, Joseph</creator><creator>Reissigl, A.</creator><creator>McLeod, David G.</creator><creator>Douglas, Thomas</creator><creator>Morgan, Ted</creator><creator>Kenny, Gerald M.</creator><creator>Ragde, Haakon</creator><creator>Boynton, Alton L.</creator><creator>Holmes, Eric H.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960815</creationdate><title>Evaluation and comparison of two new prostate carcinoma markers: Free‐prostate specific antigen and prostate specific membrane antigen</title><author>Murphy, Gerald P. ; Barren, Robert J. ; Erickson, Sheila J. ; Bowes, Victoria A. ; Wolfert, Robert L. ; Bartsch, Georg ; Klocker, Helmut ; Pointner, Joseph ; Reissigl, A. ; McLeod, David G. ; Douglas, Thomas ; Morgan, Ted ; Kenny, Gerald M. ; Ragde, Haakon ; Boynton, Alton L. ; Holmes, Eric H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4798-c0833ca6ed25e0893ff3827c9525676716ed61553e7cded4f7c0acd9ef0b53753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Antigens, Neoplasm - analysis</topic><topic>Antigens, Neoplasm - blood</topic><topic>Antigens, Surface - analysis</topic><topic>Antigens, Surface - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biopsy</topic><topic>Evaluation Studies as Topic</topic><topic>free‐prostate specific antigen</topic><topic>Glutamate Carboxypeptidase II</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasm Staging</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>prostate specific antigen</topic><topic>prostate specific membrane antigen</topic><topic>Prostate-Specific Antigen - analysis</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - chemistry</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murphy, Gerald P.</creatorcontrib><creatorcontrib>Barren, Robert J.</creatorcontrib><creatorcontrib>Erickson, Sheila J.</creatorcontrib><creatorcontrib>Bowes, Victoria A.</creatorcontrib><creatorcontrib>Wolfert, Robert L.</creatorcontrib><creatorcontrib>Bartsch, Georg</creatorcontrib><creatorcontrib>Klocker, Helmut</creatorcontrib><creatorcontrib>Pointner, Joseph</creatorcontrib><creatorcontrib>Reissigl, A.</creatorcontrib><creatorcontrib>McLeod, David G.</creatorcontrib><creatorcontrib>Douglas, Thomas</creatorcontrib><creatorcontrib>Morgan, Ted</creatorcontrib><creatorcontrib>Kenny, Gerald M.</creatorcontrib><creatorcontrib>Ragde, Haakon</creatorcontrib><creatorcontrib>Boynton, Alton L.</creatorcontrib><creatorcontrib>Holmes, Eric H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murphy, Gerald P.</au><au>Barren, Robert J.</au><au>Erickson, Sheila J.</au><au>Bowes, Victoria A.</au><au>Wolfert, Robert L.</au><au>Bartsch, Georg</au><au>Klocker, Helmut</au><au>Pointner, Joseph</au><au>Reissigl, A.</au><au>McLeod, David G.</au><au>Douglas, Thomas</au><au>Morgan, Ted</au><au>Kenny, Gerald M.</au><au>Ragde, Haakon</au><au>Boynton, Alton L.</au><au>Holmes, Eric H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation and comparison of two new prostate carcinoma markers: Free‐prostate specific antigen and prostate specific membrane antigen</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1996-08-15</date><risdate>1996</risdate><volume>78</volume><issue>4</issue><spage>809</spage><epage>818</epage><pages>809-818</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
Two new prostate cancer markers, free‐prostate specific antigen (f‐PSA) and prostate specific membrane antigen (PSMA) were recently introduced. This report summarizes a prospective two‐year multicenter test of their diagnostic or prognostic capabilities. Total PSA was also measured.
METHODS
There were four clinical groups studied: (1) 226 individuals from a screening project undergoing ultrasound and biopsy evaluation had markers obtained: (2) 68 patients suspected of having prostate cancer and undergoing 2 or more biopsies had the markers obtained on multiple occasions: (3) 100 patients undergoing radical prostatectomy had markers obtained pre‐ and post‐operatively: and (4) 31 patients with metastatic prostate cancer each had multiple samples for marker assay obtained over a 2‐year period. In all, 465 patients had one or more samples obtained and studied.
RESULTS
Free‐PSA affords little additional diagnostic advantage compared with total PSA in the screening population. The reciever operating characteristic curves for diagnostic accuracy were ranked: (1) PSA density; (2) total PSA; (3) f‐PSA; and (4) PSMA. PSMA showed the best correlation with stage of the primary tumor in the screened group. In the multiple negative biopsy group, f‐PSA varied from 12 to 21%. PSMA values were evaluated in all histologic categories. PSA density was; ce0.15 in all categories. In the prostatectomy cases PSA values postoperatively were quite low in Stage II; f‐PSA was of no value. Later, f‐PSA was increased in association with elevated total PSA values. Mean PSMA values were above normal in all postoperative time periods except in Stage III patients at 6 months to 1 year postoperatively. PSA densities were all; ce0.15. In patients with metastatic carcinoma, elevated PSMA values correlated best with a poor prognosis (clinical progression), as has been described.
CONCLUSIONS
These data suggest that f‐PSA values do not provide additional diagnostic benefit compared with total PSA in screening populations, in the presence of suspected cancer, postprostatectomy, or in metastatic disease. PSMA is of prognostic significance, especially in the presence of metastatic disease, and correlates well with the stage of disease in cancers detected in a screened population. Cancer 1996;78:809‐18.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8756376</pmid><doi>10.1002/(SICI)1097-0142(19960815)78:4<809::AID-CNCR18>3.0.CO;2-Z</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1996-08, Vol.78 (4), p.809-818 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78231718 |
| source | MEDLINE; Wiley Online Library Free Content; Access via Wiley Online Library; Alma/SFX Local Collection |
| subjects | Antigens, Neoplasm - analysis Antigens, Neoplasm - blood Antigens, Surface - analysis Antigens, Surface - blood Biological and medical sciences Biomarkers, Tumor - analysis Biomarkers, Tumor - blood Biopsy Evaluation Studies as Topic free‐prostate specific antigen Glutamate Carboxypeptidase II Humans Male Medical sciences Neoplasm Staging Nephrology. Urinary tract diseases Prognosis Prospective Studies prostate specific antigen prostate specific membrane antigen Prostate-Specific Antigen - analysis Prostate-Specific Antigen - blood Prostatectomy Prostatic Neoplasms - blood Prostatic Neoplasms - chemistry Prostatic Neoplasms - diagnosis Tumors of the urinary system Urinary tract. Prostate gland |
| title | Evaluation and comparison of two new prostate carcinoma markers: Free‐prostate specific antigen and prostate specific membrane antigen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T09%3A02%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20and%20comparison%20of%20two%20new%20prostate%20carcinoma%20markers:%20Free%E2%80%90prostate%20specific%20antigen%20and%20prostate%20specific%20membrane%20antigen&rft.jtitle=Cancer&rft.au=Murphy,%20Gerald%20P.&rft.date=1996-08-15&rft.volume=78&rft.issue=4&rft.spage=809&rft.epage=818&rft.pages=809-818&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/(SICI)1097-0142(19960815)78:4%3C809::AID-CNCR18%3E3.0.CO;2-Z&rft_dat=%3Cproquest_cross%3E78231718%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78231718&rft_id=info:pmid/8756376&rfr_iscdi=true |